Variant report
Variant | nsv555908 |
---|---|
Chromosome Location | chr11:93021163-93025749 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:1)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:1 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr11:93018701..93021080-chr11:93023667..93026629,2 | K562 | blood: |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs150886665 | chr11:93021181-93021182 | Enhancers Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
2 | rs549861105 | chr11:93021285-93021286 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
3 | rs568034211 | chr11:93021294-93021295 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
4 | rs532697732 | chr11:93021303-93021304 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
5 | rs547943269 | chr11:93021318-93021319 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
6 | rs12282420 | chr11:93021346-93021347 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
7 | rs373162904 | chr11:93021394-93021395 | Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
8 | rs547597343 | chr11:93021418-93021419 | ZNF genes & repeats Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
9 | rs566159666 | chr11:93021522-93021523 | ZNF genes & repeats Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
10 | rs530353786 | chr11:93021550-93021551 | ZNF genes & repeats Enhancers Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
11 | rs549080508 | chr11:93021668-93021669 | Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
12 | rs539748448 | chr11:93021688-93021689 | Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
13 | rs567418455 | chr11:93021753-93021754 | Weak transcription Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
14 | rs537833321 | chr11:93021820-93021821 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs557729642 | chr11:93021853-93021854 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs139339600 | chr11:93021857-93021858 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs537309711 | chr11:93021876-93021877 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs537023594 | chr11:93021929-93021930 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs555860299 | chr11:93021942-93021943 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs573783545 | chr11:93022092-93022093 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs115280387 | chr11:93022131-93022132 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs139696950 | chr11:93022157-93022158 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs553149861 | chr11:93022159-93022160 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs375605788 | chr11:93022160-93022161 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs7118644 | chr11:93022166-93022167 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
26 | rs192998879 | chr11:93022168-93022169 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs113505932 | chr11:93022169-93022170 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs184145809 | chr11:93022195-93022196 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs189478720 | chr11:93022199-93022200 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs112871578 | chr11:93022203-93022204 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs547658491 | chr11:93022207-93022208 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs4753451 | chr11:93022230-93022231 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs540418844 | chr11:93022236-93022237 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs532950947 | chr11:93022243-93022244 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs551676102 | chr11:93022273-93022274 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs375921497 | chr11:93022307-93022308 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs181836291 | chr11:93022308-93022309 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs555470364 | chr11:93022311-93022312 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs370268641 | chr11:93022333-93022334 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs567469525 | chr11:93022337-93022338 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs534798267 | chr11:93022350-93022351 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs373599832 | chr11:93022374-93022375 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs553006836 | chr11:93022447-93022448 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs375478161 | chr11:93022518-93022519 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs186490753 | chr11:93022527-93022528 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs189601753 | chr11:93022533-93022534 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs553084580 | chr11:93022580-93022581 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs572990971 | chr11:93022613-93022614 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs543445170 | chr11:93022622-93022623 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs376456597 | chr11:93022625-93022626 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Gastric cancer | 17908304 | CNVD |
Multiple myeloma | 20724749 | CNVD |
Wilms tumour | 21544195 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Non-small cell lung cancer | 21385341 | CNVD |
Intellectual disability | 22102821 | CNVD |
Autism | 22495311 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Cancer | 21637783 | CNVD |
Acute myeloid leukemia | 16864856 | CNVD |
Chronic lymphocytic leukemia | 21795749 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Neuroblastoma | 21484798 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Oral cancer | 21386901 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 20837533 | CNVD |
Breast cancer | 21264507 | CNVD |
Cervical cancer | 21063398 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Liposarcoma | 21253554 | CNVD |
Neuroblastoma | 18923524 | CNVD |
Neuroblastoma | 18664255 | CNVD |
Monoclonal gammopathy of undetermined significance | 17077331 | CNVD |
Multiple myeloma | 17077331 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Cancer | 16751803 | CNVD |
Seminomas | 18059402 | CNVD |
Cervical cancer | 21062161 | CNVD |
Prostate cancer | 18632612 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Acute lymphoblastic leukemia | 21339820 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Cancer | 22429812 | CNVD |
Breast cancer | 16608533 | CNVD |
T-cell lymphomas | 19863542 | CNVD |
Melanoma | 18172304 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Hepatocellular carcinoma | 16785998 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Breast cancer | 21858162 | CNVD |
Breast cancer | 21785460 | CNVD |
Cancer | 22183965 | CNVD |
Melanoma | 22183965 | CNVD |
Developmental delay | 21147756 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Breast cancer | 21958427 | CNVD |
Lung cancer | 18438408 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Renal cell carcinoma | 18194544 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Breast cancer | 17133270 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Acute lymphoblastic leukemia | 21098271 | CNVD |
Ductal carcinoma | 22052326 | CNVD |
Breast cancer | 21364760 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Mental retardation | 21062444 | CNVD |
Cancer | 21499728 | CNVD |
Breast cancer | 19181860 | CNVD |
Breast cancer | 17603634 | CNVD |
Mantle cell lymphoma | 19029149 | CNVD |
T-cell acute lymphoblastic leukemia | 18185524 | CNVD |
Basal cell lymphoma | 16790693 | CNVD |
Breast cancer | 21509527 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr11:93018800-93021400 | Weak transcription | H1 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
2 | chr11:93019400-93028600 | Weak transcription | Pancreatic Islets | Pancreatic Islet |
3 | chr11:93020600-93021200 | Enhancers | GM12878-XiMat | blood |
4 | chr11:93020600-93021600 | Enhancers | H1 Derived Mesenchymal Stem Cells | ES cell derived |
5 | chr11:93021200-93021800 | Flanking Active TSS | GM12878-XiMat | blood |
6 | chr11:93021400-93021600 | ZNF genes & repeats | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
7 | chr11:93021400-93021600 | Enhancers | H1 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
8 | chr11:93021600-93024400 | Weak transcription | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
9 | chr11:93021800-93023400 | Enhancers | GM12878-XiMat | blood |
10 | chr11:93022200-93022800 | Enhancers | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
11 | chr11:93022800-93023600 | Enhancers | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
12 | chr11:93023000-93023200 | Enhancers | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
13 | chr11:93023200-93028600 | Weak transcription | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
14 | chr11:93023400-93025200 | Weak transcription | GM12878-XiMat | blood |
15 | chr11:93023400-93025600 | Bivalent Enhancer | hESC Derived CD184+ Endoderm Cultured Cells | ES cell derived |
16 | chr11:93024400-93025600 | Enhancers | H1 BMP4 Derived Trophoblast Cultured Cells | ES cell derived |
17 | chr11:93024600-93025000 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
18 | chr11:93024600-93026200 | Enhancers | H9 Derived Neuronal Progenitor Cultured Cells | ES cell derived |
19 | chr11:93025000-93026200 | Enhancers | H9 Derived Neuron Cultured Cells | ES cell derived |
20 | chr11:93025200-93025600 | Enhancers | GM12878-XiMat | blood |